# A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

> **NCT06375512** · PHASE1 · COMPLETED · sponsor: **Shenzhen Shenxin Biotechnology Co., Ltd** · enrollment: 150 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** HZ Vaccine (IN001)
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT06375512
- **Lead sponsor:** Shenzhen Shenxin Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-05
- **Primary completion:** 2026-02-20
- **Final completion:** 2026-02-20
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375512, "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06375512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*